In more than 95% of CML patients, transcripts located within e13a2 (b2a2) or e14a2 (b3a2) BCR::ABL1 are associated with a p210 oncoprotein. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.